Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
323.09
-7.50 (-2.27%)
Mar 3, 2026, 1:26 PM EST - Market open
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
9.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Exelixis | 2.32B |
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
PRAX News
- 11 days ago - Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
- 11 days ago - Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 21 days ago - Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - Business Wire
- 5 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 7 weeks ago - Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - GlobeNewsWire